Paul Krenitsky
Vertex Pharmaceuticals
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul Krenitsky.
Journal of Medicinal Chemistry | 2013
Maris Vilums; Annelien J.M. Zweemer; Zhiyi Yu; Henk de Vries; Julia M. Hillger; Hannah Wapenaar; Ilse A. E. Bollen; Farhana Barmare; Raymond S. Gross; Jeremy Clemens; Paul Krenitsky; Johannes Brussee; Dean Stamos; John Saunders; Laura H. Heitman; Adriaan P. IJzerman
Preclinical models of inflammatory diseases (e.g., neuropathic pain, rheumatoid arthritis, and multiple sclerosis) have pointed to a critical role of the chemokine receptor 2 (CCR2) and chemokine ligand 2 (CCL2). However, one of the biggest problems of high-affinity inhibitors of CCR2 is their lack of efficacy in clinical trials. We report a new approach for the design of high-affinity and long-residence-time CCR2 antagonists. We developed a new competition association assay for CCR2, which allows us to investigate the relation of the structure of the ligand and its receptor residence time [i.e., structure-kinetic relationship (SKR)] next to a traditional structure-affinity relationship (SAR). By applying combined knowledge of SAR and SKR, we were able to re-evaluate the hit-to-lead process of cyclopentylamines as CCR2 antagonists. Affinity-based optimization yielded compound 1 with good binding (Ki = 6.8 nM) but very short residence time (2.4 min). However, when the optimization was also based on residence time, the hit-to-lead process yielded compound 22a, a new high-affinity CCR2 antagonist (3.6 nM), with a residence time of 135 min.
Angewandte Chemie | 2015
Weibo Yang; Shengqing Ye; Dewey Fanning; Timothy Coon; Yvonne Schmidt; Paul Krenitsky; Dean Stamos; Jin-Quan Yu
A sequential triple C-H activation reaction directed by a pyrazole and an amide group leads to the well-controlled construction of sterically congested dihydrobenzo[e]indazole derivatives. This cascade reaction demonstrates that the often problematic competing C-H activation pathways in the presence of multiple directing groups can be harvested by design to improve step economy in synthesis. Pyrazole as a relatively weak coordinating group is shown to direct Csp3-H activation for the first time.
Journal of Organic Chemistry | 2013
Jeremy Clemens; Juliana L. Asgian; Brett B. Busch; Timothy Coon; Justin Ernst; Leonard Kaljevic; Paul Krenitsky; Timothy D. Neubert; Edwin Schweiger; Andreas Termin; Dean Stamos
Efforts to substitute the cyclopropane ring in a series of aryl cyclopropylnitriles led to the discovery of an operationally simple one-pot method for Knoevenagel condensation and subsequent Corey-Chaykovsky cyclopropanation giving diastereomerically pure products as a racemic mixture of enantiomers. Method development and results for variably substituted aryl acetonitriles and aldehydes in the reaction are reported. A concise synthesis of (±)-bicifadine in two steps is provided to demonstrate the utility of the method.
Bioorganic & Medicinal Chemistry Letters | 2015
Timothy Neubert; Mehdi Numa; Justin Ernst; Jeremy Clemens; Paul Krenitsky; Michael Liu; Beth Fleck; Lisa Woody; Harmon Zuccola; Dean Stamos
Two novel series of oxazepine and diazepine based HSP90 inhibitors are reported. This effort relied on structure based design and isothermal calorimetry to identify small drug like macrocycles. Computational modelling was used to build into a solvent exposed pocket near the opening of the ATP binding site, which led to potent inhibitors of HSP90 (25-30).
Archive | 2005
Dean Wilson; Andreas P. Termin; Jesus E. Gonzalez; Lev T. D. Fanning; Timothy Neubert; Paul Krenitsky; Pramod Joshi; Dennis James Hurley; Urvi Sheth
Journal of Medicinal Chemistry | 1999
Argyrios G. Arvanitis; Paul J. Gilligan; Robert J. Chorvat; Robert Scott Cheeseman; Thomas E. Christos; Rajagopal Bakthavatchalam; James P. Beck; Anthony J. Cocuzza; Frank W. Hobbs; Richard Gerald Wilde; Charles R. Arnold; Dennis R. Chidester; Matthew A. Curry; Liqi He; Andrea Hollis; John D. Klaczkiewicz; Paul Krenitsky; Joseph P. Rescinito; Everett Latham Scholfield; Steven Culp; Errol B. De Souza; Lawrence W. Fitzgerald; Dimitri E. Grigoriadis; S. William Tam; Y.Nancy Wong; Shiew-Mei Huang,✗,◊ and; Helen L. Shen
Journal of Medicinal Chemistry | 1999
Robert J. Chorvat; Rajagopal Bakthavatchalam; James P. Beck; Paul J. Gilligan; Richard Gerald Wilde; Anthony J. Cocuzza; Frank W. Hobbs; Robert Scott Cheeseman; Matthew A. Curry; Joseph P. Rescinito; Paul Krenitsky; Dennis R. Chidester; Yarem Ja; John D. Klaczkiewicz; Hodge Cn; Aldrich Pe; Wasserman Zr; Fernandez Ch; Zaczek R; Lawrence W. Fitzgerald; Huang Sm; Shen Hl; Wong Yn; Chien Bm; Argyrios G. Arvanitis
Journal of Medicinal Chemistry | 1999
Hodge Cn; Aldrich Pe; Wasserman Zr; Fernandez Ch; Nemeth Ga; Argyrios G. Arvanitis; Robert Scott Cheeseman; Robert J. Chorvat; Ciganek E; Thomas E. Christos; Paul J. Gilligan; Paul Krenitsky; Everett Latham Scholfield; Strucely P
Archive | 2007
Pramod Joshi; Paul Krenitsky; Jesus E. Gonzalez; Jian Wang; Dean Wilson; Andreas P. Termin
Archive | 2008
Weichuan Caroline Chen; Paul Krenitsky; Andreas P. Termin; Dean Wilson